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improve cardiovascular risk, although these observations need confirmation.
DOI: https://doi.org/10.1093/gerona/glaa079





von Känel, Roland; Mills, Paul J; Dimsdale, Joel E; Ziegler, Michael G; Allison, Matthew A; Patterson,
Thomas L; Ancoli-Israel, Sonia; Pruitt, Christopher; Grant, Igor; Mausbach, Brent T (2020). Effects
of Psychosocial Interventions and Caregiving Stress on Cardiovascular Biomarkers in Family Dementia
Caregivers: The UCSD Pleasant Events Program (PEP) Randomized Controlled Trial. Journals of




Accepted for Publication by J Gerontol A Biol Sci Med Sci on February 4, 2020 
 
Effects of psychosocial interventions and caregiving stress on cardiovascular 
biomarkers in family dementia caregivers:  
The UCSD Pleasant Events Program (PEP) randomized controlled trial 
 
Running head: Caregiver intervention and circulating biomarkers 
 
Roland von Känel M.D.1,2; Paul J. Mills, Ph.D.2,3; Joel E. Dimsdale, M.D.2; 
Michael G. Ziegler, M.D.4; Matthew A. Allison, M.D.3; Thomas L. Patterson, Ph.D.2; 
Sonia Ancoli-Israel, Ph.D.2; Christopher Pruitt, B.S.3; Igor Grant, M.D.2; 
Brent T. Mausbach, Ph.D.2 
 
1 Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University 
Hospital Zurich, University of Zurich, Switzerland 
2 Department of Psychiatry, University of California San Diego, La Jolla, California, USA 
3 Department of Family Medicine and Public Health, University of California San Diego, La 
Jolla, California, USA 
4 Department of Medicine, University of California San Diego, La Jolla, California, USA 
 
Address correspondence to: 
Roland von Känel, M.D. 
Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine 
University Hospital Zurich / Culmannstrasse 8 / CH-8091 Zurich / Switzerland  




Background: This study examined whether biological mechanisms linking dementia 
caregiving with an increased risk of coronary heart disease can be modified by psychosocial 
interventions and which caregivers might benefit the most from an intervention. 
Methods: Spousal dementia caregivers were randomized to 12-week treatment with 
either a behavioral activation intervention (i.e., Pleasant Events Program PEP; n=60), or an 
active control Information and Support (IS; n=63) condition. Indicators of caregiving stress 
were assessed pre-treatment and circulating cardiovascular biomarkers were measured pre- 
and post-treatment. 
Results: There were no significant changes in biomarker levels from pre- to post-
treatment both by treatment condition and across all caregivers. Regardless of the treatment 
condition, exploratory regression analysis revealed that caregivers were more likely to show 
significant decreases in C-reactive protein (CRP) and D-dimer when their spouse had severe 
functional impairment; in interleukin (IL)-6 and CRP when they had greater distress due to 
care recipient’s problem behaviors; in tumor necrosis factor (TNF)-α when they had higher 
levels of negative affect; and in IL-6, CRP, TNF-α and D-dimer when they had higher 
personal mastery. Within the PEP group, caregivers with higher negative affect and those 
with higher positive affect were more likely to show a reduction in von Willebrand factor and 
D-dimer, respectively. Within the IS group, caregivers whose spouse had severe functional 
impairment were more likely to show a decrease in IL-6. 
Conclusions: Unlike the average caregiver, caregivers high in burden/distress and 
resources might benefit from psychosocial interventions to improve cardiovascular risk, 
although these observations need confirmation. ClinicalTrials.gov NCT02317523 





Informal caregiving for a family member has been associated with an increased risk 
of cardiovascular disease, particularly incident coronary heart disease (CHD) (1-4). The risk 
of CHD is greater in caregivers experiencing higher levels of burden and distress compared 
to their less stressed counterparts (1 2,4). Inflammatory and prothrombotic changes might 
partially explain this link as they are key contributing factors to atherosclerosis (5, 6) and 
acute coronary thrombosis (7,8). Meta-analyses demonstrated a direct association of 
circulating inflammatory and prothrombotic biomarkers, including C-reactive protein (CRP) 
(9), interleukin (IL)-6 (10), tumor necrosis factor (TNF)- (10), D-dimer (11), von 
Willebrand factor (VWF) (11), and plasminogen activator inhibitor (PAI)-1 (12), with 
incident CHD. Higher levels of CRP (13), IL-6 (14), TNF- (15) and D-dimer (16), a marker 
of increased fibrin turnover, were found in dementia caregivers compared to non-caregiving 
controls. However, findings from the two most recent systematic reviews on negative effects 
of caregiving on biomarkers of immune function, inflammation and coagulation are mixed 
(17, 18). For instance, meta-analysis showed no statistical difference in both IL-6 and CRP 
levels between caregivers and controls, although this analysis also included studies on 
caregivers for persons who are not afflicted by dementia (18). 
Whereas dementia caregiver status in itself may not strongly affect biological 
processes detectable by circulating biomarkers, various facets of a stressful caregiving 
experience could have a greater impact. For instance, after adjustment for covariates, years 
caregiving (15) and daily stressors (13) were associated with higher CRP. Both dementia 
severity (19) and caregiver distress due to problem behaviors of the care recipient (20) were 
associated with higher D-dimer. In contrast, stress buffering resources like personal mastery 
or satisfaction with leisure activities, were associated with lower PAI-1 (21) and TNF-α (22), 
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respectively. Such biomarker research helps to gain deeper insight into the pathogenic 
pathway leading from caregiver stress to coronary atherosclerosis and thrombosis. 
 Whether stress-reducing interventions improve caregivers’ cardiovascular health has 
rarely been investigated (17,23) with only one previous study from our group targeting 
biomarkers of CHD risk (24). In that trial, we showed greater reduction in IL-6, but similar 
D-dimer levels, in dementia caregivers who underwent a six-week Pleasant Events Program 
(PEP) intervention, targeting participation in pleasurable activities, compared to caregivers 
having received Information and Support (IS) (24). The present study was performed in a 
different sample of caregivers with the primary aim of extending these previous findings. We 
explored the effects of a 12-week treatment with PEP versus time-equivalent IS on changes 
in IL-6 levels, as the primary outcome and on TNF-, CRP, D-dimer, VWF and PAI-1 levels 
as secondary outcomes. We hypothesized that PEP would result in significantly greater 
reduction of IL-6 and additional biomarkers compared to IS.  
Personalized care can be fully realized only when contextual social and behavioral 
health determinants are investigated within interventions (25), bearing in mind that 
psychological treatments can also have adverse effects (26). Hence, the secondary aim of our 
study was to explore indicators of caregiving stress as predictors or moderators of biomarker 
responses to treatment. A predictor would affect biomarker responses equally for PEP and IS, 
whereas a moderator would affect the relative effect of PEP and IS on biomarker responses. 
This knowledge could inform clinicians as to whether a caregiver should be offered certain 
psychosocial interventions targeting his or her CHD risk at all and, if so, which intervention 






MATERIALS AND METHODS 
Participants 
The participants of this study were enrolled between 2/2015 and 1/2019 in the 
University of California, San Diego (UCSD) Dementia Caregiver Study for a randomized 
controlled trial aimed at improving caregiver psychobiological health through behavioral 
interventions (ClinicalTrials.gov registration number: NCT02317523). Here, we report the 
biomarker data, specifically the intervention effects on changes in the pre-specified primary 
endpoint measure IL-6 from pre- to post-treatment. Pre-specified secondary endpoints were 
changes in CRP, TNF-α, D-dimer, VWF and PAI-1 from pre- to post-treatment.  
Applying a community sampling strategy, we recruited caregivers through the UCSD 
Alzheimer’s Disease Research Center, from local support groups, through referrals from local 
caregiver agencies and other participants, and from health fairs. To be eligible, caregivers had 
to provide at least 20 hours per week of in-home care for a spouse/partner with dementia, to 
be at least 55 years of age, and to perceive at least mild psychological distress, based on a 
score ≥5 on the Patient Health Questionnare-9 (27) at study enrollment. Exclusion criteria 
were current treatment with anticoagulants, nitrates, niacin, non-selective β-blockers, aldomet 
labetalol or steroids; cognitive impairment, blood pressure >200/120 mm Hg; major 
psychiatric illnesses (e.g., schizophrenia, bipolar disorder); a diagnosis of a terminal illness 
with a life expectancy < 1 year (in caregiver or care recipient); caregiver receiving 
psychotherapy. 
The Consort flow diagram showing the flow of participants through the stages of this 
biomarker study is displayed in Figure 1. We assessed 325 participants for eligibility, of 
which 151 met our inclusion criteria and were willing to undergo treatment by random. Some 
caregivers did not provide biomarkers at post-treatment and others elected to drop out or not 
do a post-treatment assessment. Thus, for this biomarker analysis, we examined data from 
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123 dementia caregivers who provided blood samples for biomarker assessment pre- and 
post-treatment. All participants provided written consent in the study protocol approved by 
the UCSD Institutional Review Board. 
 
Interventions 
Using a randomization table, eligible caregivers were randomly assigned in a 1:1 ratio 
to one of the two intervention groups. We previously described the intervention protocol in 
detail (24). Briefly, both interventions were conducted in caregivers’ homes and consisted of 
six face-to-face therapy sessions of 60 minutes over a period of 12 weeks (i.e., the interval 
between pre- and post-treatment assessments). The experimental intervention was behavioral 
activation (i.e., the Pleasant Events Program, PEP) to reduce activity restriction and restore 
engagement in pleasurable and rewarding activities through self-monitoring, while 
simultaneously reducing negative avoidant coping responses. Behavioral activation is an 
evidence-based treatment to alleviate psychological distress, including depression and 
negative affect (NA) in caregivers (23,24). The active comparator intervention was IS, which 
consisted of providing education on dementia, community-based services available for 
caregivers, and coping with caregiving specific stressors through problem-solving, supportive 
and cognitive-behavioral therapy strategies. Caregivers receiving IS choose information 
relevant to their current circumstances to be discussed with their therapist. 
 
Measures 
The pre-treatment baseline visit consisted of an interview-based assessment by a 
trained research associate in caregivers’ home. The interview took approximately 1.5-2 hours 
and included administration of questionnaires, as well as questions about demographic 
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factors and health characteristics. A research nurse collected fasting blood samples in 
caregivers’ homes for biomarker assessments before and after treatment. 
 
Demographics, comorbidity and health behaviors 
Information on age and sex were collected and noted. Physical diseases were assessed 
by asking caregivers the question “Do you currently have, or has a doctor ever told you that 
you have any of the following health problems (heart attack, stroke, high blood pressure, 
heart disease, diabetes, high cholesterol, lung disease, liver disease, kidney problems, sleep 
apnea, cancer, thyroid disease)?” Affirmative responses were summed reflecting medical 
comorbidity (total score 0-12) (28). Smoking status was categorized into ever (i.e., all former 
plus five current smokers) vs. never smokers. The Rapid Assessment of Physical Activity 
(RAPA) scale was used to assess the amount of light, moderate and strenuous physical 
activities in a typical week; higher scores indicate greater amount of physical activity (total 
score 0-6) (29). The research associate measured weight and height to calculate the body 
mass index (BMI). 
We formed a health behavior risk score (range 0-5) that was used for statistical 
analysis. Two risk points each were assigned to obesity (BMI 30 kg/m2) and under-active 
regular light physical activity or sedentary; one risk point each was assigned to overweight 
(BMI 25 kg/m2, but <30 kg/m2), ever smoking, and under active regular physical activity. 
  
Indicators of caregiving stress 
Information on years caregiving was obtained. Functional impairment of the care 
recipient was assessed with the Activities of Daily Living Questionnaire for patients with 
dementia covering areas referring to self-care, household, employment, shopping, travel, and 
communication (30). Total scores express percent impairment (0-100%) in performing these 
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activities. We categorized care recipients into two groups, those with severe (i.e., 67-100%) 
impairment and those with moderate (i.e., 34-66%) or none-to-mild (i.e., 0-33%) impairment, 
because the latter group comprised only six individuals. Twenty-four memory, disruptive and 
depressive behaviors of the care recipient in the previous week and caregiver distress due to 
these behaviors were measured with the Revised Memory and Behavior Problem Checklist. 
Caregivers were asked to rate on a 5-point Likert scale how bothered or upset they felt by 
each behavior (0=not at all, 4=extremely; total score 0-96); higher scores indicate greater 
level of problem behavior distress which is expressed as the average item score (i.e., total 
score divided by 24) (31). The 20-item Positive and Negative Affect Scale was applied to 
assess positive (e.g., excited, active) and negative (e.g., upset, afraid) affect in the past few 
weeks (total score 10-50 for each scale); higher scores indicate greater level of positive affect 
(PA) or NA (32). For regression analyses, we divided total PA and NA scores by 2.5, a 
clinically meaningful mean scale difference (32). The 7-item Pearlin Personal Mastery scale 
was used to rate feelings of having control over one's life circumstance (e.g., “what happens 
to me in the future mostly depends on me”); higher scores indicate greater mastery (total 
score 7-28) (33). 
 
Circulating biomarkers 
Blood samples were collected in EDTA tubes for IL-6, CRP and TNF-α, and in 
sodium citrate tubes for D-dimer, PAI-1 and VWF and centrifuged for 15 min at 1,732 g 
force at 4ºC. Plasma was stored at -80ºC until analyzed in the USCD Integrative Health and 
Mind-Body Biomarker Laboratory. Concentrations of IL-6 and TNF-α were measured using 
an electrochemiluminescence-based multi-array sandwich immunoassay method through the 
MSD Human Proinflammatory Panel-1 V-PLEX 10-spot multiplex kit (Meso Scale 
Diagnostics LLC, Rockville, MD). Concentrations of CRP, PAI-1 antigen, D-dimer and 
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VWF antigen were determined with a quantitative sandwich enzyme immunoassay method 
(R&D Systems Human CRP and PAI-1 Quantikine ELISA kits, Biotechne, Minneapolis, 
MN; Thermo Scientific Human D-Dimer and VWF ELISA kits, Life Technologies, Carlsbad 
CA). Intra- and inter-assay coefficients of variation were <10% for all analyses. Assay 
sensitivities were excellent. 
 
Statistical analysis 
Data were analyzed using SPSS 25.0 for Windows (SPSS Inc., Chicago, IL) with 
level of significance at p<0.05. A few missing values for physical diseases (7 cases), BMI, 
smoking status, care recipient functional impairment, caregiver problem behavior distress, 
personal mastery, and individual biomarkers pre- and post-treatment (all ≤3 cases) were 
replaced using the expectation maximization algorithm. Because of a non-Gaussian 
distribution, biomarker values were log (base 10) transformed prior to analysis. For clarity, 
we present original units.  
Independent samples t-test and Pearson chi-square test were used to compare the PEP 
with the IS intervention group on characteristics assessed before treatment. Repeated 
measures analysis of variance was used to test for differences in biomarker levels from pre- 
to post-treatment between the PEP and IS intervention group (i.e., time-by-treatment 
interactions) with change in IL-6 levels as the primary outcome. Changes in CRP, TNF-α, D-
dimer, PAI-1 and VWF levels were secondary outcomes. Main effects for time and treatment 
were of additional interest. 
Binary endpoints facilitate individualized treatment decisions based on risk/benefit 
considerations (34, 35). Therefore, we modeled logistic regression analysis with the binary 
dependent variable “decrease” (1=yes, 0=no) to estimate the relative chance that an indicator 
of caregiving stress would be associated with a decrease in biomarker levels from pre- to 
10 
 
post-treatment, regardless the absolute value of this decrease. Accordingly, the regression 
output is organized such that odds ratios (OR) >1 indicate the relative chance of a reduction 
in biomarker levels (percentage value), with a one-unit increase in an independent variable, 
simultaneously adjusting for the others. The independent variables examined reflecting 
caregiver burden/distress were years caregiving, CR functional impairment, caregiver 
problem behavior distress and NA. The examined resources of caregivers were PA and 
personal mastery. Distressed dementia caregivers (36) and those utilizing effective coping 
skills (37) were shown to particularly benefit in terms of mental health outcomes in 
psychosocial interventions. Therefore, we hypothesized the chance of a beneficial biomarker 
response to treatment to be greater in caregivers with higher versus those with lower 
pretreatment levels of both burden/distress and resources.  
In a supplementary linear regression analysis, we tested whether there would also be a 
continuous relationship between the above indicators of caregiving stress and the percentage 
change in absolute levels of biomarkers from pre- to post-treatment. Percentage changes were 
calculated on original values followed by log transformation. Log transformed values 
deviating more than 3SDs from the sample mean were omitted for analyses, so sample sizes 
for the individual biomarker analyses range between n=119 and n=122. 
In all regression models, six indicators of caregiving stress were explored as 
predictors of biomarker responses irrespective of the treatment condition (i.e., main effects) 
and as moderators of the relative effect of each treatment condition on biomarker responses 
(i.e., interaction effects). These indicators of caregiving stress were years caregiving, care 
recipient functional impairment, problem behavior distress, NA, PA, and personal mastery. 
Adjustment was made a priori for age, sex, the number of physical diseases and the health 
behavior risk score as potentially confounding variables. Given our sample size, we allowed a 
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maximum of 12 independent variables to prevent over-adjustment in regression models. 
Model outputs indicated no concern for multicollinearity. 
 
RESULTS 
Characteristics of the sample 
Table 1 shows the characteristics of the 123 caregivers per treatment condition. 
Compared to caregivers randomized to the PEP condition (n=60), those randomized to the IS 
condition (n=63) were more frequently ever smokers; however, the health behavior risk score 
showed no group difference. There were also no significant group differences in terms of 
demographic factors, the number of comorbid physical diseases or indicators of caregiving 
stress. 
 
Biomarker levels and intervention effects 
Table 2 shows biomarker levels at pre- and post-treatment for the entire sample and 
for each treatment condition separately. The results of the repeated measure analysis of 
variance are also shown. There were no significant time-by-treatment interactions for any 
biomarker, suggesting that the PEP condition had no effect on biomarkers. There were also 
no significant time effects, suggesting that biomarker levels did not change from pre- to post-
treatment in the entire sample of caregivers regardless the treatment condition. The non-
significant treatment effects additionally suggested that biomarker levels were similar in 







Relative chance for a reduction in biomarkers from pre- to post-treatment 
Indicators of caregiving stress as predictors of a biomarker reduction 
Regardless of the randomization assignment, 56 caregivers showed a decrease and 67 
showed an increase in IL-6 levels over the 12 weeks. The corresponding numbers were 63 
and 60 for CRP, 55 and 68 for TNF-α, 66 and 57 for both D-dimer and PAI-1, and 64 and 59 
for VWF. The logistic regressions of stressors and resources on a decrease in biomarker 
levels (yes vs. no) from pre- to post-treatment, adjusted for demographic factors, the number 
of diseases and the health risk score, are summarized in Table 3. Whereas treatment was not a 
significant predictor, several indicators of caregiving stress predicted significantly and 
independently the chance for a reduction in IL-6, CRP, TNF-α and D-dimer levels over the 
12 weeks. 
Most consistently, the higher the level of personal mastery, the more likely caregivers 
showed a reduction in all of these biomarkers. In detail, for a one-unit increase on the 
mastery scale before treatment, there was a 19% greater chance for a decrease in IL-6 levels 
from pre- to post-treatment (p=0.023); the corresponding chances were 19% for CRP 
(p=0.026), 28% for TNF-α (p=0.002), and 21% for D-dimer (p=0.018) levels. As opposed to 
caregivers whose spouse, at the most, had moderate levels of functional impairment before 
treatment, caregivers with a spouse with severe impairment in activities of daily living had a 
4.8-fold and 2.6-fold greater chance for a reduction in CRP (p<0.001) and D-dimer (p=0.036) 
levels, respectively. In addition, caregivers with a one-unit increase in problem behavior 
distress prior to treatment, showed a 2.4-fold and 2.2-fold greater chance for a reduction in 
IL-6 (p=0.015) and CRP (p=0.032) levels, respectively. Caregivers with higher pre-treatment 
NA to the extent of a clinically meaningful mean scale difference had a 27% greater chance 




Indicators of caregiving stress as moderators of a biomarker reduction 
To explore whether treatment condition was a moderator of the relation between 
indicators of caregiving stress and the chance for a decrease in biomarkers from pre- to post-
treatment, we probed several interactions. There were significant interactions between 
treatment and care recipient functional impairment for IL-6 (p=0.033), between treatment and 
NA for VWF (p=0.020) and between treatment and PA for D-dimer (p=0.043). Post hoc 
probing of these interactions revealed that severe care recipient functional impairment prior 
to treatment was associated with a greater chance for a reduction in IL-6 levels in caregivers 
in the IS group (OR=3.045, 95% CI 0.793, 11.696; p=0.10) relative to those in the PEP group 
(OR=0.602, 95% CI 0.157, 2.304; p=0.46). Higher pre-treatment NA was associated with a 
greater chance for a reduction in VWF levels in caregivers in the PEP group (OR=1.185, 95% 
CI 0.911, 1.543; p=0.21) relative to those in the IS group (OR=0.797, 95% CI 0.615, 1.033, 
p=0.086). Higher pre-treatment PA was associated with a greater chance for a reduction in D-
dimer levels in caregivers in the PEP group (OR=1.008, 95% CI 0.804, 1.263; p=0.95) 
relative to those in the IS group (OR=0.548, 95% CI 0.383, 0.784; p<0.001). There were no 
significant interactions between treatment and years caregiving, problem behavior distress 
and personal mastery, respectively, for a change in any biomarker level. 
 
Percentage change in biomarkers from pre- to post-treatment 
The complementary linear regressions on (log) percentage change in biomarker levels 
from pre- to post-treatment, adjusted for demographic factors, the number of diseases and the 
health risk score, are summarized in Table 4. Treatment was not a significant predictor of the 
percentage change in any biomarker. Higher mastery before predicted a greater decrease in 
CRP (p=0.022) and TNF- (p=0.025) levels. More severe care recipient functional 
impairment before treatment predicted a greater decrease in CRP levels (p<0.001). Higher 
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levels of pre-treatment NA predicted a greater decrease in TNF- levels (p=0.015) and higher 
levels of pre-treatment PA predicted a greater decrease in D-dimer (p=0.028) levels. There 
was also a significant interaction between treatment and care recipient functional impairment 
for VWF (p<0.05). Post hoc probing showed an association between more severe care 
recipient functional impairment prior to treatment and a greater decrease in VWF levels in 
caregivers in the PEP group (B=-0.029, 95% CI: -0.199, 0.142; p=0.74) relative to those in 
the IS group (B=0.121, 95% CI: -0.049, 0.292; p=0.16). There were no significant 
interactions between treatment and years caregiving, problem behavior distress, NA, PA, and 
personal mastery, respectively, for a change in any biomarker level.  
 
DISCUSSION 
Principal finding of intervention effects on circulating biomarkers 
In this randomized controlled trial with 123 family dementia caregivers, we found no 
statistically significant decrease in circulating cardiovascular biomarkers with PEP, a brief 
behavioral activation intervention, compared to time-equivalent IS, an active control 
intervention. We further found that after 12 weeks of treatment, plasma levels of IL-6, our 
primary outcome measure, and of CRP, TNF-α, D-dimer, VWF, and PAI-1, our secondary 
outcome measures, were the same as before treatment. Therefore, neither intervention had 
any significant effect on biomarker levels over time across all caregivers. This result was 
robust, as there was also no significant main effect for treatment on biomarker outcomes in 
the fully adjusted regression analyses taking into account demographic factors, medical 
comorbidity, health behaviors and caregiver stressors and resources. Thus, we infer that by 
participating in either PEP or IS for 12 weeks, the average caregiver, even when showing 




The findings of the current trial partially contrast with those of our previous one in 
which we found a significant decrease in IL-6 with PEP compared to IS after six weeks of 
treatment (24). Differences in the study design might account for this discrepancy, including 
the different treatment duration, varying therapist characteristics and that mild psychological 
distress was an inclusion criterion only in the current trial. Consistently, neither trial showed 
a difference in D-dimer levels between the two treatment conditions. Clearly, before a 
definite verdict can be made as to whether psychosocial interventions are able to improve a 
biomarker-based cardiovascular risk profile in dementia caregivers, further randomized 
controlled trials are needed. Different interventions could also be tested (17,23), some of 
which have shown, for instance, potential to lower blood pressure (38,39), another important 
cardiovascular risk factor that is highly prevalent in dementia caregivers (40). 
 
Secondary exploratory findings  
Intriguing observations flow from our secondary observations. About half of the 
caregivers showed a decrease and the other half an increase in their biomarker levels over the 
12-week study, explaining why on average the change in biomarkers in our sample was null. 
Furthermore, despite the fact that we found no simple effects of psychosocial interventions 
on biomarkers, we found that several indicators of caregiver burden/distress and resources 
were significantly predictive for a decrease in biomarker levels across all caregivers. To a 
lesser extent, indicators of caregiving stress were also significant moderators of the relative 
effect of PEP or IS on reductions in biomarkers. However, as our trial lacked a wait-list 
control condition, there is a possibility that the observed biomarker reductions, proposed as a 
function of stressors and resources, could reflect time instead of treatment effects. 
Furthermore, when interpreting these results, one must consider that they are based on a 
number of exploratory analyses, which may lead to spurious findings. 
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With these limitations in mind, either PEP or IS could be offered to caregivers whose 
spouse has severe functional impairment, or who have high levels of problem behavior 
distress, both NA and PA, or mastery in an attempt to lower biomarker levels. Most 
obviously, those with higher personal mastery, an important coping strategy and resilience 
factor associated with positive physical outcomes in dementia caregivers (41), were more 
likely to show a decrease in IL-6, CRP, TNF-α, and D-dimer levels altogether. Similarly, 
intervention trials have shown a greater benefit regarding mental health outcomes in 
dementia caregivers with high distress (32) and good coping skills (33). In turn, if a caregiver 
does not endorse sufficient stress or resources, cardiovascular harm might even increase with 
both these interventions. The latter perhaps because both situations could inflict stress, being 
treated when not feeling distressed or having to realize that resources are too low to translate 
the skills taught to everyday life.  
Regarding moderator effects, we found some indication that caregivers in the PEP 
group were more likely to benefit in terms of a decrease in VWF and D-dimer when they had 
high level of NA and PA, respectively. One explanation could be that PEP was originally 
designed to target depressive symptoms (23), and PEP also improved NA in our previous 
clinical trial when compared with IS after six weeks (24). In turn, caregivers in the IS group 
were more likely to show a reduction in IL-6 when their spouse had severe functional 
impairment, maybe because in this scenario pragmatic aids to manage everyday life as a 
caregiver becomes all the more important. Effects might vary between biomarkers, as 
caregivers with a spouse with severe functional impairment prior to treatment had greater 
reduction in VWF when being in the PEP as opposed to the IS group. Of the biomarkers we 
assessed, VWF is arguably the most responsive to sympathetic activation (42), and it could 
be that PEP lowered VWF through a dampening of sympathetic nerve outflow in these 
caregivers. However, the present study was not designed to investigate biobehavioral 
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mechanisms explaining main and moderating effects of stressors and resources on biomarker 
outcomes. The mechanisms presumably involved will have to be examined elsewhere, 
including improvements in both autonomic nervous system and hypothalamic-pituitary 
adrenal axis function, perceived distress and coping skills (17,23).  
Although fewer in number than in the logistic regression analysis, similar significant 
and independent associations between indicators of caregiving stress and percentage changes 
in biomarker levels emerged in a supplementary linear regression analysis. For instance, 
greater mastery was significantly predictive for the chance of a decrease in IL-6, but not for 
its magnitude. However, a clinician would primarily like to know whether an individual 
caregiver would show a reduction in biomarkers or not, but not so much to what extent. This 
is much like when a decision has to be made if, for instance, antihypertensive medication 
should be started in a patient with high blood pressure. 
 
Potential clinical relevance 
Although the role of biomarkers investigated for coronary sclerosis and thrombosis 
has been established (9-16,43,44), offering new targets for cardiovascular therapy (45), the 
clinical relevance of increased inflammation in family caregivers is a matter of debate (17, 
18). Bearing the exploratory nature of our analyses in mind, our study suggests that with 
appropriate treatment some family dementia caregivers’ physical health could indeed benefit 
from lowering inflammation, as well as coagulation biomarkers, like IL-6, CRP, TNF-α, and 
D-dimer. Further studies are worth pursuing this hypothesis. Also, whereas the full sequence 
of stressors and resources to inflammation (46) and coagulation (42) to CHD remains to be 
established, our findings might reach beyond implications for caregiver cardiovascular 
health. This is exemplified for IL-6, a cytokine that shows robust responses to psychosocial 
stress (47). The IL-6 signaling axis is involved in numerous chronic inflammatory diseases 
18 
 
(48), and circulating IL-6 shows associations with numerous metabolites in older adults (49). 
Accordingly, high IL-6 levels have for instance been associated with frailty (50), longitudinal 
changes in brain function in older adults (51), and perceived physical fatigability in men and 
women aged 50-96 years (52). In agreement with this literature, a recent study showed high 
IL-6 levels were predictive of emergency department visits in dementia caregivers during a 
follow-up of 15 months (53). 
 
Limitations 
We did not achieve to enroll the target sample size of 200 participants, so limited 
statistical power is an issue. The analyses on predictors and treatment moderators of 
biomarker outcomes were secondary, did not adjust for multiple comparison and thus are to 
be understood as hypothesis testing justified by the fact that research like this is still rare. 
Since only four of the numerous interactions tested between treatment and six different 
indicators of caregiving stress were statistically significant, these effects could be spurious 
and should be interpreted with caution. At least some of the effects of predictors on changes 
in biomarkers could be explained by regression to the mean because no adjustments were 
made for pre-treatment levels of biomarkers; technically, this is not possible for measures of 
a dichotomous change (any increase vs. any decrease in a particular biomarker). We reported 
on biomarker data assessed before and after treatment, while the two-year follow-up data are 
still being collected and analyzed. Our findings may not translate to caregivers of a spouse 
without dementia, to significantly younger caregivers taking care of a parent with dementia, 
and to caregivers providing end of life care (54). Consistent with the healthy caregiver 
hypothesis (55), medical comorbidity was rather low in our sample for this age. Due to the 
sample size, we were not able to adjust for factors that could have influenced biomarker 




The Pleasant Events Program is unlikely a more effective treatment than IS in 
lowering biomarkers of increased CHD risk in family dementia caregivers after 12 weeks. 
However, family dementia caregivers who show both high levels of stressors and resources 
prior to treatment could benefit from psychosocial interventions in terms of an improved 
cardiovascular risk profile. This knowledge is novel, although bases on exploratory analyses, 
and thus should be confirmed in further studies before personalized treatment 
recommendations can be made for dementia caregivers. 
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Table 1. Pre-treatment characteristics of 123 study participants by treatment condition 





Age (years), mean (SD) 72.5 (7.6) 73.4 (7.5) 0.513 
Sex (female), n (%) 47 (78.3%) 48 (77.2%) 0.777 
Years caregiving, mean (SD) 5.33 (3.76) 4.40 (2.99) 0.131 
Physical diseases (n), mean (SD) 1.50 (1.19) 1.75 (1.31) 0.277 
Body mass index (kg/m2), mean (SD) 26.6 (5.0) 28.1 (6.2) 0.133 
Ever smoking, n (%) 20 (33.3) 34 (54.0) 0.021 
Physical activity, mean (SD) 3.33 (1.70) 3.63 (1.56) 0.307 
Health behavior risk score, mean (SD) 2.25 (1.40) 2.40 (1.45) 0.569 
Severe functional impairment of CR, n (%) 36 (60.0) 27 (42.9) 0.057 
CR problem behaviors, mean (SD) 11.1 (4.1) 12.4 (4.1) 0.094 
CG problem behavior distress, mean (SD) 2.53 (0.63) 2.59 (0.58) 0.629 
Negative affect, mean (SD) 20.6 (7.3) 21.6 (6.2) 0.424 
Positive affect, mean (SD) 33.2 (7.3) 33.7 (6.9) 0.689 
Personal mastery, mean (SD) 12.0 (2.8) 12.7 (3.4) 0.263 
 









Table 2. Biomarker levels pre- and post-treatment and intervention effects 
Biomarker Treatment condition Pre-treatment Post-treatment P 
IL-6 (pg/mL) PEP + IS (n=123) 0.67 (0.43-1.11) 0.68 (0.41-1.28)  
 PEP (n=60) 0.68 (0.41-1.05) 0.67 (0.39-1.18)  
 IS (n=63) 0.66 (0.50-1.26) 0.68 (0.49-1.53)  
 Time-by-treatment 
interaction 
  0.854 
 Time effect   0.764 
 Treatment effect   0.165 
CRP (mg/L) PEP + IS (n=123) 1.65 (0.64-3.43) 1.40 (0.71-3.20)  
 PEP (n=60) 1.25 (0.57-3.08) 1.21 (0.55-2.78)  
 IS (n=63) 1.73 (0.68-4.66) 1.53 (0.78-3.55)  
 Time-by-treatment 
interaction 
  0.685 
 Time effect   0.813 
 Treatment effect   0.120 
TNF- 
(pg/mL) 
PEP + IS (n=123) 1.82 (1.54-2.43) 1.89 (1.57-2.41)  
 PEP (n=60) 1.88 (1.55-2.42) 1.87 (1.47-2.48)  
 IS (n=63) 1.78 (1.54-2.46) 1.91 (1.58-2.30)  
 Time-by-treatment 
interaction 
  0.363 
 Time effect   0.434 





PEP + IS (n=123) 5.09 (4.21-5.87) 4.90 (3.91-5,97)  
 PEP (n=60) 4.79 (4.02-5.95) 4.75 (3.79-5.96)  
 IS (n=63) 5.13 (4.30-5.85) 5.15 (4.28-6.12)  
 Time-by-treatment 
interaction 
  0.530 
 Time effect   0.169 
 Treatment effect   0.302 
PAI-1 (ng/mL) PEP + IS (n=123) 2.27 (1.31-3.83) 2.15 (1.23-3.80)  
 PEP (n=60) 2.04 (1.18-3.82) 1.83 (1.09-3.57)  
 IS (n=63) 2.44 (1.43-3.92) 2.37 (1.40-3.95)  
 Time-by-treatment 
interaction 
  0.722 
 Time effect   0.244 
 Treatment effect   0.395 
VWF (mg/L) PEP + IS (n=123) 13.5 (8.0-19.6) 13.3 (8.4-19.8)  
 PEP (n=60) 14.8 (8.0-19.9) 15.3 (9.0-19.4)  
 IS (n=63) 12.6 (7.0-18.2) 11.7 (7.7-20.6)  
 Time-by-treatment 
interaction 
  0.421 
 Time effect   0.453 
 Treatment effect   0.383 
 




CRP, C-reactive protein; IL, interleukin; IS, information support; PAI, plasminogen activator 































Assessed for eligibility (n= 325) 
Excluded (n= 174) 
 Not meeting inclusion criteria (n=117) 
 Declined to participate (n=50) 
 Other reasons (n=7) 
Included in analysis (n=60) 
 Missing biomarker data (n=4) 
Post-treatment follow-ups completed 
(n=64) 
Withdrawn/lost to follow-up (n=11) 
 Unable to contact (n=1) 
 Caregiver health (n=2) 
 Refused assessment/too busy (n=8) 
Allocated to the Pleasant Events Program 
intervention (n=75) 
 Received allocated intervention (n=75) 
 Did not receive allocated intervention 
(n=0) 
Post-treatment follow-ups completed 
(n=69) 
Withdrawn/lost to follow-up (n=7) 
 Caregiver died (n=1) 
 Caregiver health (n=1) 
 Refused assessment/too busy (n=5) 
Allocated to the Information & Support 
intervention (n=76) 
 Received allocated intervention (n=76) 
 Did not receive allocated intervention 
(n=0) 
Analyzed (n=63) 








Table 3. Logistic regression models for the relative chance for a decrease in biomarker levels from pre- to post-treatment (n=123) 
















































































































































Values are odds ratios (OR) with 95% confidence interval. An OR >1.0 indicates the relative chance of a reduction in the concentration of a 
circulating biomarker with a one-unit increase in a predictor variable. All predictors were entered in one block. Significance level: * p<0.05, ** 
p<0.01, *** p<0.001 






Table 4. Linear regression models for the associations with (log) percentage change in biomarker levels from pre- to post-treatment  
















































































































































Values are unstandardized coefficients B with 95% confidence interval. Significance level: * p<0.05, ** p<0.01 
CR, care recipient, CRP, C-reactive protein; IL, interleukin; PAI, plasminogen activator inhibitor; NF, tumor-necrosis factor; VWF, von 
Willebrand factor 
